The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Open accessAbstract
BACKGROUND: Effective ways to prevent arthropathy in severe hemophilia are unknown. METHODS: We randomly assigned young boys with severe hemophilia A to regular infusions of recombinant factor VIII (prophylaxis) or to an enhanced episodic infusion schedule of at least three doses totaling a minimum of 80 IU of factor VIII per kilogram of body weight at the time of a joint hemorrhage. The primary outcome was the incidence of bone or cartilage damage as detected in index joints (ankles, knees, and elbows) by radiography or magnetic resonance imaging (MRI). RESULTS: Sixty-five boys younger than 30 months of age were randomly assigned to prophylaxis (32 boys) or enhanced episodic therapy (33 boys). When the boys reached 6 years of age, 93% of those in the prophylaxis group and 55% of those in the episodic-therapy group were considered to have normal index-joint structure on MRI (P=0.006). The relative risk of MRI-detected joint damage with episodic therapy as compared with prophylaxis was 6.1 (95% confidence interval, 1.5 to 24.4). The mean annual numbers of joint and total hemorrhages were higher at study exit in the episodic-therapy group than in the prophylaxis group (P<0.001 for both comparisons). High titers of inhibitors of factor VIII developed in two boys who received prophylaxis; three boys in the episodic-therapy group had a life-threatening hemorrhage. Hospitalizations and infections associated with central-catheter placement did not differ significantly between the two groups. CONCLUSIONS: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00207597 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although effective, ERT is limited by an approximately 40% noncompliance rate, costs ≥$200,000 annually, and advances arthropathy.172, 173, 174, 175”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [172]
Citations
Cites
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
NILSSON, I. M., BERNTORP, E., LÖFQVIST, T., & PETTERSSON, H. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00546.x · Cited by 961
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
ALEDORT, L. M., HASCHMEYER, R. H., PETTERSSON, H., & THE ORTHOPAEDIC OUTCOME STUDY GROUP (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00815.x · Cited by 611
A Radiologic Classification of Hemophilic Arthropathy
PETTERSSON, H., AHLBERG, Å., & NILSSON, I. M. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198006000-00018 · Cited by 549
Proceedings: A more uniform measurement of factor VIII inhibitors.
Ck, K., Aledort, L. M., Aronson, D. D., Counts, R., Edson, van Eys, J., Fratantoni, J. C., Green, D., Hampton, J., Hilgartner, M. W., et al. (1975) · PubMed · Cited by 346
Barriers to compliance with prophylaxis therapy in haemophilia
Hacker, M. R., Geraghty, S., & Manco-Johnson, M. (2001) · Haemophilia · doi:10.1046/j.1365-2516.2001.00534.x · Cited by 261
Self-citationAhlberg, Å. (1965) · Acta Orthopaedica Scandinavica · doi:10.3109/ort.1965.36.suppl-77.01 · Cited by 252
Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors
Soucie, J. M. (2004) · Blood · doi:10.1182/blood-2003-05-1457 · Cited by 244
Self-citationIorio, A., Marchesini, E., Marcucci, M., Stobart, K., & Chan, A. K. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003429.pub4 · Cited by 192
Nuss, R., Kilcoyne, R. F., Geraghty, S., Shroyer, A. L. W., Rosky, J. W., Mawhinney, S., Wiedel, J., & Manco‐Johnson, M. (2000) · Haemophilia · doi:10.1046/j.1365-2516.2000.00383.x · Cited by 159
Self-citationLee, C. A., Kessler, C. M., Varon, D., Martinowitz, U. P., Heim, M., Kreuz, W., Escuriola‐Ettingshausen, C., Funk, M. J., SCHMIDT, H., & Kornhuber, B. (1998) · Haemophilia · doi:10.1046/j.1365-2516.1998.440413.x · Cited by 154
Research works printed but not linked: 5
- Robinson PM, 1967, Can Med Assoc J, 97, 559
- Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis. Medical bulletin #193. New York: National Hemophilia Foundation, March 11, 1994.
- Stobart K, 2006, Cochrane Database Syst Rev, 2, CD003429
- Kasper CK, 1975, Thromb Diath Haemorr, 34, 612
- Report on the Universal Data Collection Program. Atlanta: Centers for Disease Control and Prevention, 2005;7(1):28. (Accessed July 18, 2007, athttp://www.cdc.gov/ncbddd/hbd/documents/UDC7%281%29.pdf.)
Cited by
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A. K., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinas, A., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M. C., et al. (2013) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,927
“A dental evaluation is advisable before initiating long-term bisphosphonate therapy [28,29].”
BackgroundTherapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundDefinitions in hemophilia: communication from the SSC of the ISTH
Blanchette, V. S., Key, N. S., Ljung, L. R., Manco‐Johnson, M. J., van den Berg, H. M., & Srivastava, A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12672 · Cited by 761
Self-citationCurrent clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“replacement therapy (ERT) delivered prophylactically to prevent or on demand for bleeding.(172,173) Although effective, ERT is limited by an approximately 40% noncompliance rate, costs R$200,000 annually, and advances arthropathy.”
MethodAAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708483 · Cited by 694
Metadata
- Authors
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G. A., Thompson, A. A., McRedmond, K., Soucie, J. M., Austin, H., & Evatt, B. L.
- Affiliations
- University of Colorado Denver (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-08-09
- Volume
- 357
- Issue
- 6
- Pages
- 535-544
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2167801052
- Cited by
- 1,950
- References
- 27
- Citations by year
- 2026: 57 · 2025: 70 · 2024: 98 · 2023: 115 · 2022: 106 · 2021: 123 · 2020: 127 · 2019: 110 · 2018: 114 · 2017: 107 · 2016: 123 · 2015: 116 · 2014: 131 · 2013: 116 · 2012: 112
- FWCI
- 45.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (U27/CCU812106, R00069)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hemophilia A, severe hemophilia, prophylaxis, episodic treatment, recombinant factor VIII, joint destruction, factor VIII inhibitors, joint hemorrhage, children, central venous catheter complications
- MeSH terms
- Child, Child, Preschool, Drug Administration Schedule, Factor VIII, Follow-Up Studies, Hemarthrosis, Hemophilia A, Hemorrhage, Humans, Infant, Infusions, Intravenous, Joint Diseases, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. https://app.cochat.ai/papers/10.1056/nejmoa067659
- The paper
- Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., Valentino, L. A., Hoots, W. K., Buchanan, G. R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., . . . Evatt, B. L. (2007). Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa067659
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.